Another ongoing clinical trial including NKT-214 with pembrolizumab in solid tumors (NCT03138889), IL-2 in combination with nivolumab for advanced NSCLC (NCT03215810). This evidence concerns the gene IL2 and non-small cell lung carcinoma.